Ziopharm Oncology, Inc.

-0.04 (-2.40%)
Layoffs, Products, Earnings Announcements

Ziopharm Oncology Announces Over 50% Reduction In Workforce

Published: 09/27/2021 21:23 GMT
Ziopharm Oncology, Inc. (ZIOP) - Ziopharm Oncology Announces Strategic Reduction in Workforce and Extension in Cash Runway.
Ziopharm Oncology Inc - Cost Reductions Expected to Extend Cash Runway Into First Half of 2023.
Ziopharm Oncology Inc - Over 50% Reduction in Personnel.
Ziopharm Oncology Inc - First Patient in Its Tcr-t Library Phase I/ii Clinical Trial is Expected to Be Dosed in 1h2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.